Member Info for AnthonyW

Can't remember if the ibs trial was being compared to another treatment. Generally futility analysis is against a comparator. However I take it to mean that the data they have gathered so far suggests its safe enough to progress from a phase 2 and they have seen enough of a signal that it could work (generally that's what phase 3 trials are about)

Excellent share of slides! IBS is furthest ahead. If it makes it alone would be a massive boost to SP.

I wonder if it will be a poster at ESMO conference? That would be a good place and high profile.

Thanks for sharing. Quite a compelling presentation. I work in cancer. The data they present for the combination of pembro + bacteria to rekindle a treatment response is compelling. I didn't quite see timelines for when more data will be presented.

Are we expecting any results to be published from our trials? If so when? In particular is there anything at ESMO about using our products in combination with pembrolizumab?

They have quite a large COPD footprint in their pipeline

Doesn't say much. Usual corporate talk that we're committed to helping (without saying how)

I was saying I doubt kodak are manufacturer of interferon as they are mainly concerned with reagents. My point was alpha Biologics originally made it for synairgen. I am wondering who they are working with now....

Don't think they are making Biologics just reagents

Does anyone know is currently making the interferon? In the past it was a company called Alpha Biologics in Cambridge.

I was answering FOXYKIWI's question about whether it was IV or Neb version. I looked at clinicaltrials.gov website only. I will check out FARN now.

Its an IV prep and will be run by GILEAD. No place for SNG I believe.